J Frystyk1, C Skjaerbaek, E Vestbo, S Fisker, H Orskov. 1. Institute of Experimental Clinical Research, Medical Research Laboratories and Medical Department M, Aarhus University Hospital, Aarhus, Denmark. jan@frystyk.dk
Abstract
BACKGROUND: Obese subjects show major abnormalities in the growth hormone (GH)/insulin-like growth factor (IGF) system. Furthermore, they are prone to develop Type 2 diabetes, but the impact of diabetes plus obesity on the GH/IGF system remains unknown. METHODS: We compared overnight fasting serum levels of free and total (extractable) IGF-I and -II, IGF-binding protein (IGFBP) -1, -2 and -3, and the high affinity GH-binding protein (GHBP) in matched groups of lean subjects (n=26) and obese subjects without (n=24) and with (n=29) Type 2 diabetes. Two groups (n=7) of healthy and Type 1 diabetic subjects were also studied. RESULTS: Non-diabetic obese subjects had increased free IGF-I and -II, total IGF-II, IGFBP-3 and GHBP, reduced IGFBP-1 and -2 (p<0.05), but normal total IGF-I, when compared to lean subjects. In obese Type 2 diabetics free IGF-I was insignificantly reduced by 9% (p=0.3), when compared to non-diabetic obese subjects. However, the concentration was not significantly elevated when compared to that of lean controls (p=0.13). Also IGFBP-1 and total IGF-I were normal in obese Type 2 diabetics, whereas free and total IGF-II and IGFBP-3 remained elevated to a similar extent as in simple obesity (p<0.05). In contrast, GHBP was further increased and IGFBP-2 further reduced in obese Type 2 diabetics (p<0.05). In Type 1 diabetics total IGF-I and -II, and IGFBP-3 were normal. In contrast, free IGF-I and -II and GHBP were markedly reduced, whereas IGFBP-1 and -2 were increased (p<0.05). CONCLUSIONS: Simple obesity was associated with marked changes in the GH/IGF system. Many of these abnormalities were unaffected by the concomitant presence of Type 2 diabetes (total IGF-I, free and total IGF-II and IGFBP-3). However, some changes became accentuated (GHBP and IGFBP-2), while others (free IGF-I and IGFBP-1) were no longer present. Notably, the impact of Type 1 diabetes on the GH/IGF system was clearly different from that of Type 2 diabetes. Copyright 1999 John Wiley & Sons, Ltd.
BACKGROUND:Obese subjects show major abnormalities in the growth hormone (GH)/insulin-like growth factor (IGF) system. Furthermore, they are prone to develop Type 2 diabetes, but the impact of diabetes plus obesity on the GH/IGF system remains unknown. METHODS: We compared overnight fasting serum levels of free and total (extractable) IGF-I and -II, IGF-binding protein (IGFBP) -1, -2 and -3, and the high affinity GH-binding protein (GHBP) in matched groups of lean subjects (n=26) and obese subjects without (n=24) and with (n=29) Type 2 diabetes. Two groups (n=7) of healthy and Type 1 diabetic subjects were also studied. RESULTS:Non-diabetic obese subjects had increased free IGF-I and -II, total IGF-II, IGFBP-3 and GHBP, reduced IGFBP-1 and -2 (p<0.05), but normal total IGF-I, when compared to lean subjects. In obese Type 2 diabetics free IGF-I was insignificantly reduced by 9% (p=0.3), when compared to non-diabetic obese subjects. However, the concentration was not significantly elevated when compared to that of lean controls (p=0.13). Also IGFBP-1 and total IGF-I were normal in obese Type 2 diabetics, whereas free and total IGF-II and IGFBP-3 remained elevated to a similar extent as in simple obesity (p<0.05). In contrast, GHBP was further increased and IGFBP-2 further reduced in obese Type 2 diabetics (p<0.05). In Type 1 diabetics total IGF-I and -II, and IGFBP-3 were normal. In contrast, free IGF-I and -II and GHBP were markedly reduced, whereas IGFBP-1 and -2 were increased (p<0.05). CONCLUSIONS: Simple obesity was associated with marked changes in the GH/IGF system. Many of these abnormalities were unaffected by the concomitant presence of Type 2 diabetes (total IGF-I, free and total IGF-II and IGFBP-3). However, some changes became accentuated (GHBP and IGFBP-2), while others (free IGF-I and IGFBP-1) were no longer present. Notably, the impact of Type 1 diabetes on the GH/IGF system was clearly different from that of Type 2 diabetes. Copyright 1999 John Wiley & Sons, Ltd.
Authors: Manal M Hassan; Reham Abdel-Wahab; Ahmed Kaseb; Ahmed Shalaby; Alexandria T Phan; Hashem B El-Serag; Ernest Hawk; Jeff Morris; Kanwal Pratap Singh Raghav; Ju-Seog Lee; Jean-Nicolas Vauthey; Gehan Bortus; Harrys A Torres; Christopher I Amos; Robert A Wolff; Donghui Li Journal: Gastroenterology Date: 2015-03-30 Impact factor: 22.682
Authors: G Aimaretti; M Boschetti; G Corneli; V Gasco; D Valle; M Borsotti; A Rossi; A Barreca; L Fazzuoli; D Ferone; E Ghigo; F Minuto Journal: J Endocrinol Invest Date: 2008-05 Impact factor: 4.256
Authors: Esteban N Gurzov; Melanie Tran; Manuel A Fernandez-Rojo; Troy L Merry; Xinmei Zhang; Yang Xu; Atsushi Fukushima; Michael J Waters; Matthew J Watt; Sofianos Andrikopoulos; Benjamin G Neel; Tony Tiganis Journal: Cell Metab Date: 2014-06-19 Impact factor: 27.287
Authors: Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler Journal: Diabetes Metab Res Rev Date: 2009-01 Impact factor: 4.876
Authors: Julio Licinio; Sinan Caglayan; Metin Ozata; Bulent O Yildiz; Patricia B de Miranda; Fiona O'Kirwan; Robert Whitby; Liyin Liang; Pinchas Cohen; Shalender Bhasin; Ronald M Krauss; Johannes D Veldhuis; Anthony J Wagner; Alex M DePaoli; Samuel M McCann; Ma-Li Wong Journal: Proc Natl Acad Sci U S A Date: 2004-03-09 Impact factor: 11.205